Comparing prognosis for #BRCA1 #BRCA2 and #nonBRCA breast cancer in #Portugal #SABCS23 BRCA associated with worse prognosis SABCS

Presented today at #SABCS23 and published in JAMA results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers OncoAlert SABCS AACR Università di Genova Ospedale San Martino Genova #bcsm Link here: jamanetwork.com/journals/jama/…

Dear Colleagues at #SABCS23 🇺🇸 Presenting the OncoAlert 🚨RoundUp for DAY3⃣ For a Deeper look REGISTER at OncoAlert360.com Discussing ✅GS02-13🤰by Matteo Lambertini, MD PhD 🇮🇹 JAMA ✅AVIATOR🛩️ ✅IDEA💡 ✅PREFERABLE -EFFECT ✅TROPION BREAST0⃣1⃣ ✅POSITIVE ➕ ✅NSABP B-51☢️

#NATALEE trial Adjuvant #ribociclib in HR+/HER2- #EBC Benefit across all subgroups! 📍#IDFS: ∆ 3.1% absolute benefit at 3y, producing a ⬇️ 25% risk reduction 📍#DDFS: ∆ 2.7% absolute benefit at 3y SABCS #SABCS23

#KATHERINE trial at #SABCS23 Adjuvant #TDM1 vs. Trastuzumab in #residual disease post NACT + anti-HER2 in #HER2 positive breast cancer > Final IDFS 📍∆ 13.7% absolute difference at 7y, benefit across all subgroups > 2nd OS IA 📍∆ 4.7% absolut difference at 7y

#INAVO120 primary analysis #inavolisib + #palbociclib + fulvestrant > Poor prognosis disease characteristics > #mPFS 15.0 vs. 7.3 months, HR 0.43! > #mOS NR vs. 31.1 months, HR 0.64! > #ORR 58.4% vs. 25.0% #SABCS23

Honored to have presented my poster at ESMO BREAST 2024 ESMO - Eur. Oncology #esmobreast24! Thank you to Dr Soraia Lobo-Martins and all the team. A special thanks to Dr Anne M May for including our data in the final #esmobreast24 highlights 🥰😍 #sexuality_BC

Excited to share our latest letter to the editor in @AnnOncol: "Tumour Heterogeneity in Molecular Imaging for Breast Cancer" 🔬📄. Explore our insights on the challenges and advancements in molecular imaging. #Oncology #BreastCancer #MedicalResearch Thanks to all the team!

Just out in Cells MDPI: "CDK4/6 inhibitors on circulating cells in patients with metastatic breast cancer" 🧬📄. Read more: doi.org/10.3390/cells1… #BreastCancer #Oncology #CancerResearch #CDK46Inhibitors

Already 12m since my arrival at Institut Jules Bordet Instituut and no better way to celebrate the ESMO - Eur. Oncology fellowship, which will allow me to continue my 🇧🇪journey! Thank you for this amazing experience Lucia Del Mastro, Matteo Lambertini, MD PhD Evandro de Azambuja, MD, PhD Elisa Agostinetto Soraia Lobo-Martins Chiara Dauccia

Presented at #ASCO24 and now out in Journal of Clinical Oncology results of our study on clinical behavior of #BreastCancer in young #BRCA carriers and importance of prediagnostic awareness of germline BRCA status..grateful to all #BRCABCYcollaboration #bcsm OncoAlert Link: ascopubs.org/doi/pdf/10.120…

Extended adj endocrine therapy for #patients with HR+/HER2 neg #early #breastcancer: who needs more? ESMO Open Soraia Lobo-Martins; Franzoi Maria Alice Elisa Agostinetto Matteo Lambertini, MD PhD Lucia Del Mastro Luca Arecco, MD Thai Chiara Dauccia OncoAlert sciencedirect.com/science/articl…

At #ESMOBreast25 Soraia Lobo-Martins opens the mini oral session2️⃣ with #ROSALINE, investigator-initiated trial testing neoadjuvant entrectinib + ET in #lobular breast cancer Primary endpoint (RCB 0/1 rate) was not met 🛑 but translational analyses are ongoing 🔬 OncoAlert

Mini oral session at #ESMOBreast25 with Soraia Lobo-Martins from Institut Jules Bordet Instituut presenting results of #ROSALINE trial showing limited activity of neoadjuvant #entrectinib plus endocrine therapy in lobular #BreastCancer #ESMOAmbassadors ESMO - Eur. Oncology OncoAlert #bcsm Philippe Aftimos, MD  Evandro de Azambuja, MD, PhD

The #ROSALINE trial results are here! Did not meet primary endpoint but #ROS1i #Entrectinib has shown activity in early stage #ILC! Our study #REPLOT using the next-gen #ROS1i #Repotrectinib is currently enrolling #mILC in the US MD Anderson Cancer Center Amazing presentation by the

As always, a deep, engaging and detailed discussion of Soraia Lobo-Martins Sixten Theodoros Foukakis presentations by Hope Rugo 👏👏👏 #ESMOBreast25 #ESMOAmbassadors ESMO - Eur. Oncology

Grateful to #SuzetteDelaloge for reporting the results of our meta-analysis on alcohol and BC in the #ESMObreast25 takeaways! 🙏🏼 As highlighted, there isn’t a #safe dose of alcohol consumption, and even light consumption increases the risk of BC! Evandro de Azambuja, MD, PhD OncoAlert

Honoured to see our results in #ROSALINE trial featured by Rebecca Dent at the #ESMOBreast25 highlights in #early #breastcancer. Growing interest in novel strategies for early #lobular BC! Looking forward to the #REPLOT study in the advanced setting.

This is a crucial issue that requires attention. Waiting an entire year for a response should not be acceptable, but unfortunately, it happens too often. In Latin America, only 14% of cancer research papers are published the same year they are completed. It is necessary to

Join us at #ASCO25 tomorrow to discuss the efficacy of immune checkpoint inhibitors in patients with CNS metastases from solid tumors, a group often overlooked in clinical trials Soraia Lobo-Martins Diogo Martins Branco Evandro de Azambuja, MD, PhD Marco Tagliamento Elisa Agostinetto Eva Blondeaux Matteo Lambertini, MD PhD